文献速递关节外科

术前凝血功能障碍患者行全关节置换术使用氨甲环酸能否使并发症风险正常化?一项匹配等效性分析

Does the Use of Tranexamic Acid in Patients Who Have Preoperative Coagulopathy Undergoing Total Joint Arthroplasty Normalize Their Risk of Complications? A Matched Equivalence Analysis.
PubMed 文献 · J Arthroplasty · 2023-05-25

本研究回顾性分析2012至2019年接受初次全关节置换术并使用的氨甲环酸的患者,其中230例术前存在凝血功能障碍,匹配689例无凝血功能障碍患者。等效性检验显示,凝血功能障碍患者接受氨甲环酸后失血风险与无凝血功能障碍患者等效;全髋关节置换术凝血功能障碍患者输血比例较高(11.8% vs 5.32%,P=0.022),但两组并发症无差异。

要点

  • 全髋关节置换术凝血功能障碍患者接受氨甲环酸后输血比例高于无凝血功能障碍患者(11.8% vs 5.32%,P=0.022)。
  • 全髋关节置换术凝血功能障碍患者报告估计失血量高于无凝血功能障碍患者(243 vs 207 mL,P=0.040)。
  • 全髋与全膝关节置换术凝血功能障碍患者接受氨甲环酸后失血风险与无凝血功能障碍患者等效,且并发症无差异。

核心结论

  • 接受氨甲环酸的全髋关节置换术凝血功能障碍患者输血风险增加,但全髋与全膝关节置换术并发症无差异,且失血风险与无凝血功能障碍患者相比正常化。

研究设计与样本

  • 回顾性综述2012至2019年接受初次全关节置换术并使用氨甲环酸的230例术前凝血功能障碍患者(127髋、103膝),匹配689例无凝血功能障碍并使用氨甲环酸的患者,采用2个单侧检验(TOST)进行等效性分析。

主要发现

  • 全髋关节置换术凝血功能障碍患者与无凝血功能障碍患者相比,血红蛋白无差异,但报告估计失血量较高(243 vs 207 mL,P=0.040),需输血患者比例较高(11.8% vs 5.32%,P=0.022)。
  • 全膝关节置换术凝血功能障碍患者与无凝血功能障碍患者相比,血红蛋白、估计失血量及需输血患者比例均无差异。
  • 全髋与全膝关节置换术两组患者内科或外科并发症均无差异。
  • 等效性检验显示,接受氨甲环酸的全髋与全膝关节置换术凝血功能障碍患者失血风险与接受氨甲环酸的无凝血功能障碍患者等效,差异有统计学意义。

关键数值与推荐

  • 凝血功能障碍定义为国际标准化比值>1.2、部分凝血活酶时间>35秒或血小板计数<150,000/mL。
  • 等效性界值设定为术后血红蛋白下降组间差异±1 g/dL,基于临床相关差异1 g/dL的假设。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While patients who have a preoperative coagulopathy have an increased risk of perioperative blood loss, tranexamic acid (TXA) has been shown to decrease the risk of complications in this subset. However, a direct comparison of the use of TXA in coagulopathic and noncoagulopathic patients has not been performed. In addition to comparing differences in decreases in hemoglobin, transfusions, and complications, this study examined whether the use of TXA in coagulopathic patients normalized the risk of blood loss relative to matched noncoagulopathic patients. METHODS: We performed a retrospective review of 230 patients who had a preoperative coagulopathy and underwent primary total joint arthroplasty (127 hips, 103 knees) from 2012 to 2019 and received TXA. Coagulopathy was defined as international normalized ratio >1.2, partial thromboplastin time >35 seconds, or platelet count <150,000/mL (mL). A matched comparison group of 689 patients who did not have a coagulopathy and received TXA was identified. A 2 1-sided test (TOST) analysis was performed to test for equivalence. Assuming a clinically relevant difference of 1 g/dL in postoperative decrease in hemoglobin, the equivalence margin was set as ±1 g/dL between the groups. RESULTS: When comparing coagulopathic and noncoagulopathic patients, total hip arthroplasty (THA) patients had no differences in hemoglobin, but had an increased reported estimated blood loss (243 versus 207 mL, P = .040) as well as an increased percent of patients requiring blood transfusions (11.8 versus 5.32%, P = .022). Total knee arthroplasty (TKA) patients had no differences in hemoglobin, estimated blood loss, or percent of patients requiring transfusion. There were no differences in medical or surgical complications for both groups for THA and TKA patients. Equivalence testing for both groups revealed statistical significance that THA and TKA coagulopathic patients receiving TXA had an equivalent risk of blood loss compared to noncoagulopathic patients receiving TXA. CONCLUSION: Coagulopathic patients receiving TXA and undergoing THA had an increased risk of receiving a transfusion; however, there were no differences in complications for both TKA and THA, as well as a normalized risk of blood loss when compared to noncoagulopathic patients. LEVEL OF EVIDENCE: III.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Meghpara MM, Goh GS, Ciesielka KA, et al. Does the Use of Tranexamic Acid in Patients Who Have Preoperative Coagulopathy Undergoing Total Joint Arthroplasty Normalize Their Risk of Complications? A Matched Equivalence Analysis. J Arthroplasty. 2023. PMID: 37244426. doi:10.1016/j.arth.2023.05.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。